Bradley Merrill Thompson Quoted in “How FDA Is Backing the Use of Artificial Intelligence in Telemedicine”

Wearable Technologies

Bradley Merrill Thompson, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Wearable Technologies, in “How FDA Is Backing the Use of Artificial Intelligence in Telemedicine,” by Sam Draper.

Following is an excerpt:

Telemedicine, also known as e-medicine, is the remote delivery of healthcare services, including tests and consultations, over the telecommunications infrastructure. Telemedicine allows health care professionals to evaluate, diagnose and treat patients at a distance using telecommunications technology.

For telemedicine to be truly useful, the patient must be able to collect and transmit a variety of data the healthcare professional needs in order to assess the patient’s health, writes Bradley Merrill Thompson in MobiHealthNews.

Artificial intelligence (AI) can help with data collection by instructing patients how to use medical technology that collects data. AI can help physicians sort through and analyze the data they receive, and it can even help deliver therapy. …

Apart from image analysis, FDA has come out with a new redraft of its Clinical Decision Support Software Guidance last September that is much more flexible in its treatment of AI.

“FDA has provided a road map for guidance-system technologies in ways that they can be used to facilitate telemedicine. Unfortunately this roadmap can’t be found in any guidance, and no doubt the rules will continue to evolve. But it appears that FDA is willing to be creative and flexible. And, nearly all of this was even before COVID-19 created an urgency around the use of telemedicine. The future is looking pretty bright for these technologies,” Thompson wrote in his report.